GlassScriptPhysician profile
Prateek Mendiratta
NPI 1104960525
$290,306.70
in general payments reported to CMS, 2019-2025
28 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $17K · 2021: $58K · 2022: $44K · 2023: $66K · 2024: $32K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Consulting Fee: $32K · Travel and Lodging: $10K · Food and Beverage: $3,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,310.00 |
| Consulting Fee | $32,212.50 |
| Travel and Lodging | $10,206.16 |
| Food and Beverage | $3,492.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $111,575.58 | 2020-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $87,572.59 | 2020-2025 | Lynparza, Enhertu, Imfinzi |
| Astellas Pharma US INC | $33,274.91 | 2020-2025 | Padcev |
| Pfizer INC. | $25,964.49 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $20,518.42 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $2,920.81 | 2023-2025 | |
| Eisai INC. | $2,360.12 | 2021-2025 | |
| Genzyme Corporation | $1,863.70 | 2021-2025 | |
| Array Biopharma INC | $1,817.70 | 2019-2025 | Braftovi |
| Janssen Biotech, INC. | $1,395.65 | 2021-2025 | Erleada, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $297.93 | 2022-2025 | |
| Tempus Ai, INC | $117.86 | 2024-2025 | Xt Cdx |
| Abbvie INC. | $110.18 | 2024-2025 | |
| Blue Earth Diagnostics | $91.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.24 | 2022-2025 | Opdivo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $45.93 | 2024 | Padcev |
| Tolmar Pharmaceuticals, INC. | $42.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $34.38 | 2024 | Akeega, Erleada, Balversa |
| Amgen INC. | $34.19 | 2023 | Lumakras |
| Ipsen Biopharmaceuticals, INC | $33.02 | 2024-2025 | Onivyde |
| Genentech USA, INC. | $32.60 | 2024-2025 | Tecentriq, Tecentriq Hybreza |
| Sumitomo Pharma America, INC. | $30.25 | 2023-2025 | Orgovyx |
| Gilead Sciences, INC. | $22.60 | 2025 | Trodelvy |
| Geron Corporation | $17.99 | 2025 | Rytelo |
| Incyte Corporation | $16.74 | 2025 | Monjuvi, Zynyz |
| Genmab U.S., INC. | $16.13 | 2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $16.03 | 2025 | |
| Myovant Sciences INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prateek Mendiratta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.